Albireo Pharma, Inc. (ALBO): Price and Financial Metrics

Albireo Pharma, Inc. (ALBO): $44.15

-0.10 (-0.23%)

POWR Rating

Component Grades














  • Sentiment is the dimension where ALBO ranks best; there it ranks ahead of 71.63% of US stocks.
  • The strongest trend for ALBO is in Value, which has been heading down over the past 178 days.
  • ALBO's current lowest rank is in the Quality metric (where it is better than 5.44% of US stocks).

ALBO Stock Summary

  • With a year-over-year growth in debt of 1,024.42%, ALBIREO PHARMA INC's debt growth rate surpasses 98.14% of about US stocks.
  • Over the past twelve months, ALBO has reported earnings growth of 311.67%, putting it ahead of 95.21% of US stocks in our set.
  • Revenue growth over the past 12 months for ALBIREO PHARMA INC comes in at 432.68%, a number that bests 97.95% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to ALBIREO PHARMA INC, a group of peers worth examining would be NHWK, NVCN, ACAD, SPRO, and KOPN.
  • ALBO's SEC filings can be seen here. And to visit ALBIREO PHARMA INC's official web site, go to

ALBO Valuation Summary

  • In comparison to the median Healthcare stock, ALBO's EV/EBIT ratio is 155.56% lower, now standing at -6.
  • Over the past 191 months, ALBO's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for ALBO.

Stock Date P/S P/B P/E EV/EBIT
ALBO 2023-02-17 15.8 9.0 -6.9 -6.0
ALBO 2023-02-16 15.9 9.1 -7.0 -6.1
ALBO 2023-02-15 15.9 9.1 -7.0 -6.1
ALBO 2023-02-14 16.0 9.2 -7.0 -6.1
ALBO 2023-02-13 15.9 9.1 -7.0 -6.1
ALBO 2023-02-10 16.0 9.2 -7.0 -6.1

ALBO Growth Metrics

    The 4 year price growth rate now stands at 18.49%.
  • The year over year revenue growth rate now stands at 420.86%.
  • Its year over year price growth rate is now at -7.12%.
Over the past 49 months, ALBO's revenue has gone up $45,223,000.

The table below shows ALBO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 57.391 -115.322 -131.145
2022-06-30 51.223 -113.175 -36.259
2022-03-31 45.445 -108.252 -32.731
2021-12-31 40.579 -107.559 -34.03
2021-09-30 10.774 -121.863 -47.867
2021-06-30 9.241 -120.352 -135.696

ALBO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ALBO has a Quality Grade of D, ranking ahead of 12.41% of graded US stocks.
  • ALBO's asset turnover comes in at 0.035 -- ranking 346th of 680 Pharmaceutical Products stocks.
  • LCI, MBIO, and XNCR are the stocks whose asset turnover ratios are most correlated with ALBO.

The table below shows ALBO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.035 1 -72.830
2021-03-31 0.034 1 -28.871
2020-12-31 0.035 1 -35.203
2020-09-30 0.057 1 -49.355
2020-06-30 0.064 1 -125.682
2020-03-31 0.061 1 30.641

ALBO Price Target

For more insight on analysts targets of ALBO, see our ALBO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $75.86 Average Broker Recommendation 1.25 (Strong Buy)

ALBO Stock Price Chart Interactive Chart >

Price chart for ALBO

ALBO Price/Volume Stats

Current price $44.15 52-week high $45.23
Prev. close $44.25 52-week low $16.02
Day low $43.99 Volume 1,241,200
Day high $44.90 Avg. volume 704,539
50-day MA $37.97 Dividend yield N/A
200-day MA $25.15 Market Cap 913.95M

Albireo Pharma, Inc. (ALBO) Company Bio

Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders. The company is based in Boston, Massachusetts.

ALBO Latest News Stream

Event/Time News Detail
Loading, please wait...

ALBO Latest Social Stream

Loading social stream, please wait...

View Full ALBO Social Stream

Latest ALBO News From Around the Web

Below are the latest news stories about ALBIREO PHARMA INC that investors may wish to consider to help them evaluate ALBO as an investment opportunity.

Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: Should You Buy?

Mirum Pharmaceuticals, Inc. (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | March 1, 2023

Is Albireo Pharma (ALBO) Stock Outpacing Its Medical Peers This Year?

Here is how Albireo Pharma (ALBO) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.

Yahoo | March 1, 2023

FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille Syndrome

Bylvay (odevixibat) granted Priority Review by U.S. FDAASSERT study demonstrated efficacy of Bylvay in pruritus, bile acids and sleep with a low drug-related diarrhea rate in Alagille patientsApproval in second indication would more than double Bylvay market opportunity BOSTON, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced that the U.S. Food and Drug

Yahoo | February 14, 2023

Why These Two Biotech Stocks Blasted Higher This Week

Two somewhat under-the-radar biotech companies saw their share prices soar this week after agreeing to be acquired. CinCor Pharma (NASDAQ: CINC) is being bought out by deep-pocketed pharmaceutical company AstraZeneca, while Albireo Pharma (NASDAQ: ALBO) is set to be owned by France-based peer Ipsen. Both of these deals are very lucrative, to the point where CinCor's stock rocketed 146% over the course of the week, and Albireo shot 92% skyward, according to data compiled by S&P Global Market Intelligence.

Yahoo | January 13, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

We're starting off the week with a look at the biggest pre-market stock movers traders need to know about on Monday morning!

William White on InvestorPlace | January 9, 2023

Read More 'ALBO' Stories Here

ALBO Price Returns

1-mo 1.49%
3-mo 127.93%
6-mo 135.72%
1-year 44.38%
3-year 150.85%
5-year 32.38%
YTD 104.30%
2022 -7.21%
2021 -37.91%
2020 47.56%
2019 3.63%
2018 -4.18%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9057 seconds.